deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT03382639

A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia

Sponsor: Neurocrine Biosciences

Conditions Schizophrenia
Interventions Luvadaxistat Placebo
Updated 20 times since 2018 Last updated: Jan 30, 2024 Started: Jan 4, 2018 Primary completion: Dec 29, 2020 Completion: Jan 12, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Neurocrine Biosciences and has accumulated 20 data snapshots since 2018. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Apr 2019 · 7 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Aug 2020 · 12 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Mar 2024 · 23 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2022 — Mar 2024 [monthly]

    Completed PHASE2

▶ Show 15 earlier versions

  1. Jan 2022 — Apr 2022 [monthly]

    Completed PHASE2

  2. Sep 2021 — Jan 2022 [monthly]

    Completed PHASE2

  3. Feb 2021 — Sep 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  7. Aug 2019 — Aug 2020 [monthly]

    Recruiting PHASE2

  8. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  9. Apr 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  10. Sep 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

  11. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  12. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  13. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  14. Feb 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Jan 2018 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Neurocrine Biosciences
  • Takeda
Data source: Neurocrine Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Augusta, United States , Austin, United States , Barcelona, Spain , Bari, Italy , Berlin, Germany , Brescia, Italy , Bydgoszcz, Poland , Everett, United States , Gaithersburg, United States and 40 more locations